It works differently than many currently available treatments because it targets three hormone receptors involved in metabolism and appetite regulation: GLP-1 GIP Glucagon Because of this triple-action mechanism, retatrutide has shown very promising results in early clinical trials, with some participants experiencing significant reductions in body weight
GIP + Glucagon Simultaneously activates GIP receptors (enhancing insulin secretion and fat metabolism) and glucagon receptors (increasing energy expenditure and lipolysis)
These findings align closely with prior cardiovascular outcome trials and solidify the evidence base by demonstrating consistent benefits in broader patient populations treated in clinical practice
doi:10.1007/s00125-008-1149-y Buteau J
Semaglutide works on GLP-1 only, while Retatrutide works on GLP-1, GIP, and glucagon together, so labs study it for stronger effects on appetite, insulin, and energy burn
doi: 10.1016/j.ajem.2024.01.010 53 ZhangJMaYZuQWangXZhangY